DeiCell Systems Information

DeiCell Systems provides FDA-aligned, audit-ready GMP and QMS systems for early-stage biotech and medtech companies scaling manufacturing without full-time senior quality leadership. We help teams define phase-appropriate quality infrastructure that meets FDA and ISO 13485 requirements without overengineering, delays, or delivery risk. As organizations move from research into manufacturing, quality requirements increase quickly. Without clear structure, teams often overbuild systems, lose alignment between Quality and Operations, and risk missed timelines. DeiCell Systems is typically brought in at this transition point to define what is required now versus later and to stabilize execution. Our work aligns with FDA 21 CFR Part 820, ISO 13485:2016, ICH Q10, and 21 CFR Part 11. We design phase-appropriate QMS infrastructure including document control, CAPA, change control, training and competency, internal audits, and inspection readiness. Systems are built to be usable by lean teams while remaining scalable and audit-ready. Most clients are pre-seed to Series B startups scaling operations or manufacturing without dedicated internal quality leadership. Our focus is minimum-necessary compliance, clear decision rules, and governance that prevents overengineering while protecting regulatory credibility. DeiCell Systems helps life science teams scale responsibly by turning regulatory requirements into practical, defensible quality systems that support growth, inspections, and investor confidence.